140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations

  1. Park, K.
  2. Tan, E.-H.
  3. Zhang, L.
  4. Hirsh, V.
  5. O'Byrne, K.
  6. Boyer, M.
  7. Yang, J.
  8. Mok, T.
  9. Kim, M.
  10. Paz-Ares, L.
Zeitschrift:
Journal of Thoracic Oncology

ISSN: 1556-1380,  1556-0864

Datum der Publikation: 2016

Ausgabe: 11

Nummer: 4

Seiten: S117-S118

Art: Artikel

DOI: 10.1016/S1556-0864(16)30250-7 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus